PHARMACYTE BIOTECH, INC. — Income Charts
12 quarters of history · ending 2026-01-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Operating Expenses
Income Breakdown
Revenue
$0
Cost of Revenue
—
Gross Profit
—
R&D↓-21.2% -$25K
$93K
SG&A
—
D&A
—
Operating Income↓-120.6% -$1M
$-2M
EBITDA↓-120.6% -$1M
$-2M
Interest Expense
$0
Interest Income
—
Tax Provision
—
Net Income↑+124.5% +$4M
$747K
Gross Margin
—
Operating Margin
—
Net Margin
—
NOL Carryforwards
$3M
ETR (Continuing Operations)
—
ETR Federal Statutory
—
Operating Lease Cost↑+1.8% +$125
$7K
Revenue YoY Variation
—
Income YoY Variation↓-169.2pts
-120.6%
Revenue QoQ Variation
—
Income QoQ Variation↓-67.1pts
-53.9%